Stocktoria

Nasus Pharma Ltd NSRX

NYSE · stock · Pharmaceutical Preparations · website · IPO 2025-08-13 · LEI

Nasus Pharma Ltd statistics & valuation

Market cap$29.7M
P / S0.0×
P / B10.7×
Net margin-0.5%
FCF margin-0.4%
Return on capital-172.6%

Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-0.50% 20242025
Gross margin (%)
20242025
Operating margin (%)
-0.40% 20242025
Return on equity (%)
-211.60% 20242025
Shares outstanding
7.4M 9.0M 20242025
Net debt ($)
20242025
Share buybacks ($)
20242025
Return on assets (%)
-213.70% -117.00% 20242025
Free cash flow margin (%)
-0.40% 20242025
Debt / equity (×)
20242025
EPS ($)
-$0.22 -$0.72 20242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024
Operating margin-0.4%—
Net margin-0.5%—
FCF margin-0.4%—
Return on assets-117.0%-213.7%
Return on equity-211.6%47.7%
Current ratio2.240.12

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.